New hope for cancer pain in seniors with kidney disease?
NCT ID NCT07421674
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether hydromorphone sustained-release tablets can safely relieve moderate to severe cancer pain in elderly patients who also have kidney issues. Researchers will compare these patients to those with normal kidney function, monitoring pain relief, kidney function, and side effects over 4 weeks. The goal is to find a better way to manage pain without harming the kidneys.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- hydromorphone sustained-release tablets
- What this could lead to
- If successful, this could provide a safer pain management option for elderly cancer patients with kidney issues, improving their quality of life.
- What could go wrong
- This is a small, early-stage study with only 62 participants, so results may not apply broadly. The drug may still cause side effects like neurotoxicity or worsen kidney function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 62 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Feb 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Study participants will be selected from the patient population presenting at the Oncology Department of Taian City Tumor Hospital, a regional tertiary cancer care center in Shandong Province, China. Recruitment will specifically target older adult patients with cancer who are being evaluated for and initiate standardized opioid therapy for moderate-to-severe cancer pain at this institution.
- Ages
-
65 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age ≥ 65 years. 2. Pathologically or cytologically confirmed malignant tumor. 3. Opioid-naïve patients with moderate-to-severe cancer pain (Numerical Rating Scale score ≥ 4). 4. Renal function meeting one of the following criteria at baseline: 1）Mild-to-moderate renal insufficiency group: 30 mL/min/1.73m² ≤ estimated glomerular filtration rate (eGFR) \< 90 mL/min/1.73m². 2）Normal renal function group: eGFR ≥ 90 mL/min/1.73m². 5.Expected survival period ≥ 3 months. 6.Ability to take oral medication and cooperate with study assessments. 7.Willing to participate voluntarily and able to provide signed informed consent. Exclusion Criteria: 1. Severe renal insufficiency (eGFR \< 30 mL/min/1.73m²) or requirement for renal replacement therapy. 2. Severe hepatic insufficiency (alanine aminotransferase / aspartate aminotransferase ≥ 2.5 times the upper limit of normal or Child-Pugh Class C). 3. Paralytic ileus. 4. Pain of unclear origin or pain that is solely acute/incident pain. 5. Symptoms or history of diseases such as intracranial hypertension, head injury, cerebral aneurysm, or other central nervous system disorders. 6. Symptoms of prostatic hypertrophy, thyroid dysfunction, or urethral stricture. Symptoms of asthma, respiratory obstruction, or respiratory failure. 7. Known allergy or hypersensitivity to hydromorphone or oxycodone. 8. Use of monoamine oxidase inhibitors within 14 days prior to enrollment. 9. Participation in any other clinical trial within 1 month prior to enrollment. 10. Any other condition considered by the investigator as unsuitable for participation in this study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer pain are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Tai'an Caner Hospital
Tai’an, Shandong, 271000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a video game teach cancer patients to tame their pain?
- Can a ketone drink shield kidneys?
- Can calming inflammation shield the heart?
- Can a kidney drug stop acute injury from becoming chronic?
- Could a single radiation dose ease bone pain as well as five?
- Talking therapy may offer a path away from opioids for cancer survivors